Author: Andrei Bilog M.Sc., CAPM
A story I still think about…
Don’t believe everything you read in headlines.
My dad used to say, “If it’s too good to be true, it probably is.” And honestly, that’s stuck with me.
It’s like when you see “cage-free” on a carton of eggs and picture chickens roaming freely—only to learn they’re still packed tightly indoors.
Or when a supplement claims to “boost your immune system overnight”—with little real evidence behind it.
We’ve gotten used to this kind of exaggeration in everyday life.
But when that same mindset shows up in biotech?
That’s when it becomes a real problem.
🧪 What happened with ImmunityBio?
In March 2026, ImmunityBio saw its stock drop over 20% after receiving a warning letter from the U.S. Food and Drug Administration (FDA).
Here’s the issue:
Their cancer therapy Anktiva was approved only for a specific type of bladder cancer
But ads and podcast appearances suggested it could:
Treat all cancers
Act as a cancer vaccine
Work as a standalone cure (Reuters)
The FDA called these claims false or misleading, emphasizing that:
The drug’s actual indication is narrow
There’s no supporting data for universal cancer treatment claims (Reuters)
Even worse:
The ads omitted risks and safety info
Suggested incorrect routes of administration (like injections instead of intravesical delivery) (PharmExec)
📉 Result? Investor confidence dropped instantly.
🧠 Why this matters (especially for students)
If you’re in healthcare, biotech, or even still in school—this is bigger than just a news story.
This is about scientific integrity.
1. Science ≠ storytelling (but people confuse the two)
In school, you might feel pressure to:
“Make your results sound better”
“Stretch your conclusion a little”
“Sell your project”
But in real biotech?
👉 That same behavior becomes regulatory risk.
The FDA specifically regulates drug promotion because:
Patients can be misled
Clinicians may make unsafe decisions
Trust in science can erode
And once trust is gone, it’s incredibly hard to rebuild.
2. Evidence matters more than excitement
In clinical research, claims must match evidence.
For example:
Single-arm trials (like some early oncology studies) cannot prove broad efficacy
Endpoints like response rate ≠ cure
This aligns with broader scientific consensus:
Overstating results can distort clinical interpretation and harm patients (Ioannidis, 2005)
Miscommunication in medical research is a known contributor to poor healthcare decisions (Hoffmann & Del Mar, 2017)
👉 In other words:
What you say about data matters just as much as the data itself.
3. This happens more than you think
What stood out to me most?
The FDA had already warned the company before about similar issues. (U.S. Food and Drug Administration)
This wasn’t a one-time mistake—it was a pattern.
And honestly… that’s something I see in students too:
Repeating the same study mistakes
Ignoring feedback
Thinking “it’s not a big deal”
Until suddenly—it is.
🔬 The deeper lesson (Mindset Shift)
Let me bring this back to you.
When your experiment fails
When your interview doesn’t land
When your results don’t look impressive
You have two choices:
Reframe it honestly → grow
Repackage it dishonestly → risk everything
ImmunityBio chose the second path in its messaging.
And the market—and regulators—responded immediately.
⚡ TAKEAWAY
If you’re building a career in healthcare or biotech:
👉 Your credibility is your currency.
Not your GPA.
Not your resume.
Not even your technical skills.
Your integrity.
Because in this field:
Patients are listening
Regulators are watching
And the truth always surfaces
📚 References
Hoffmann, T. C., & Del Mar, C. (2017). Patients’ expectations of the benefits and harms of treatments, screening, and tests: A systematic review. JAMA Internal Medicine, 177(3), 407–419. https://doi.org/10.1001/jamainternmed.2016.8254
Ioannidis, J. P. A. (2005). Why most published research findings are false. PLoS Medicine, 2(8), e124. https://doi.org/10.1371/journal.pmed.0020124
U.S. Food and Drug Administration. (2026). Warning letter to ImmunityBio regarding promotional claims. (U.S. Food and Drug Administration)
Reuters. (2026). ImmunityBio shares fall on FDA warning letter over cancer therapy claims. (Reuters)
Barron’s. (2026). FDA flags misleading cancer claims. (Barron's)
Associated Press. (2026). FDA warning on misleading cancer drug promotion. (AP News)
Disclaimer: This article was assisted by AI-based language tools (ChatGPT, OpenAI) for drafting and organization. All content was reviewed by the author, and all claims are supported by peer-reviewed sources.
More about Andrei Bilog
A dedicated professional and educator, serving as the Founder and Editor-in-Chief of UPkeeping Newsletter. His expertise stems from a powerful combination of experience: 7+ years in the biotech industry, a current MBA pursuit at the University of Illinois Urbana-Champaign, and his role as an adjunct professor of Human Anatomy & Physiology. As the President of the Beta Psi Omega National Chapter, Andrei is passionate about student mentorship and guiding the next generation of lifelong learners toward strong career and wellness foundations.
